نيويورك، 31 أكتوبر 2010 [ME NewsWire]:
(بزنس واير)– أعلنت شركة "نيلسن بي في"، الرائدة عالمياً في مجال المعلومات والقياس والإعلام، اليوم نتائجها المالية للربع والأشهر التسعة المنتهية في 30 سبتمبر 2010.
وبلغت عائدات الأشهر الثلاثة المنتهية في 30 سبتمبر 2010، 1،289 مليون دولار أمريكي، بزيادة نسبتها 5% عن عائدات الأشهر الثلاثة المنتهية في 30 سبتمبر 2009، والتي بلغت 1،227 مليون دولار. ولدى استثناء تأثيرات تقلب أسعار العملات*، تكون الإيرادات قد شهدت زيادة بنسبة 7% في الأشهر الثلاثة المذكورة.
ووصلت العائدات التشغيلية للأشهر الثلاثة المنتهية في 30 سبتمبر 2010 إلى 201 مليون دولار مقارنة مع خسارة تشغيلية قدرها 326 مليون دولار في الأشهر الثلاثة المنتهية في 30 سبتمبر 2009. وشملت نتائج عام 2010 مبلغ 11 مليون دولار متعلقة بتكاليف إعادة الهيكلة. أمّا نتائج 2009، فقد شملت 524 مليون دولار من التكاليف المتعلقة بضعف الشهرة في سبتمبر 2010 وبغيرها من الأصول غير الملموسة، فضلاً عن إعادة الهيكلة. وبعد تعديل هذه الأمور وباستثناء تأثيرات تقلّب أسعار العملات*، يكون الدخل التشغيلي قد ازداد بنسبة 10%.
ووصلت عائدات الأشهر التسعة المنتهية في 30 سبتمبر 2010، إلى 3،755 ملايين دولار، بزيادة نسبتها 7% مقارنة مع عائدات الأشهر التسعة المنتهية في 30 سبتمبر 2009 والتي بلغت 3،511 ملايين دولار. ولدى استثناء تأثيرات تقلّب أسعار العملات*، تكون عائدات الأشهر التسعة قد ازدادت بنسبة 6%.
وبلغ دخل التشغيل للأشهر التسعة المنتهية في 30 سبتمبر من العام الحالي، 525 مليون دولار مقارنة مع خسارة تشغيلية وصلت إلى 42 مليون دولار في الأشهر التسعة المنتهية في 30 سبتمبر 2009. وتضمنت نتائج العام 2010 مبلغ 33 مليون دولار من التكاليف المتعلقة بإعادة الهيكلة. وأظهرت نتائج عام 2009 مبلغ 533 مليون دولار من التكاليف المتعلقة بضعف الشهرة في سبتمبر 2009 وبأصول أخرى غير ملموسة، فضلاً عن إعادة الهيكلة. وبعد تعديل هذه العوامل وباستثناء تأثيرات تقلّب أسعار العملات*، يكون الدخل التشغيلي قد ازداد بنسبة 10%.
وبلغت الأرباح المجمعة قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة وغيرها من التعديلات المسموح بها بموجب التسهيلات الائتمانية الكبيرة المضمونة (الأرباح المجمعة قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة) 1.415 مليون دولار للأشهر الإثني عشرة المنتهية في 30 سبتمبر 2010. ويشار إلى أنّ هذا المعيار يدخل ضمن مبادئ المحاسبة غير المعتمدة، ويرجى مراجعة المعيار المذكور دناه لتسوية الدخل من العمليات المتواصلة التي بلغت قيمتها 191 مليون دولار للأشهر الإثني عشرة المنتهية في 30 سبتمبر 2010.
وكما في 30 سبتمبر 2010، بلغ مجموع الدين الإجمالي 8.571 مليون دولار، في حين بلغت موازنات النقد 420 مليون دولار. وبلغت نفقات رأس المال 226 مليون دولار في الأشهر التسعة المنتهية في 30 ديسمبر 2010، مقارنة مع 204 مليون دولار في الأشهر التسعة المنتهية في 30 ديسمبر 2010.
المؤتمر الصوتي والبث الشبكي
ستعقد شركة "نيلسن" مؤتمراً صوتياً للكشف عن أرباحها، يستضيفه المدير التنفيذي للشركة برايان ج. ويست في تمام الساعة التاسعة صباحًا بالتوقيت الشرقي لأمريكا وذلك بتاريخ 28 أكتوبر 2010. وسيتم بث المؤتمر صوتيًّا ومباشرة على موقع http://en-us.nielsen.com/main/about/investor_relations وسيتوفر أرشيف على الموقع الإلكتروني بعد الاتصال. وإضافة إلى ذلك، سيتم نشر رابط للتقرير المالي للشركة لهذا الربع بصيغة 10-Q على الرابط http://en-us.nielsen.com/main/about/investor_relations.
بيانات استشرافية
يتضمن هذا البيان الصحفي معلومات قد تشكل بيانات استشرافية مصاغة وفقاً لحكم "الملجأ الآمن" التابع لقانون إصلاح تقاضي الأوراق المالية الخاصة عام 1995. ويمكن التعرف على هذه البيانات بكلمات مثل "يتوقع" و"يجب" و"قد" و"سوف" وغيرها من العبارات المشابهة. وتخضع هذه البيانات للمخاطر والشكوك وقد تختلف النتائج والأحداث الفعلية بشكل كبير عن المتوقّع. وقد تشمل العوامل المؤدية إلى ذلك على سبيل المثال لا الحصر، الأوضاع الاقتصادية العامة وأوضاع الأسواق التي تعمل فيها "نيلسن" وسلوك العملاء والمزودين والمنافسين والتطورات التقنية إضافة إلى قواعد قانونية وتنظيمية قد تؤثر على أعمال الشركة، علمًا أنّ لائحة العوامل هذه ليست شاملة. ولا تعد الشركة مسؤولة عن تحديث أي بيانات استشرافية خطية أو شفهية نقوم بها نحن أو بإسمنا نتيجة لمعلومات جديدة أو أحداث مستقبلية أو عوامل أخرى.
نبذة عن شركة "نيلسن"
تعد شركة "نيلسن" رائداً عالمياً في مجال المعلومات والقياس والإعلام، وتحتل مكانة متميزة في مجالات معلومات التسويق والمستهلك، والمعلومات الإعلامية، والأبحاث عن الإنترنت وفاعليته، وقياس أنماط استخدام المحمول والمعارض التجارية والمطبوعات الاقتصادية والأنشطة ذات الصلة. وتمارس هذه الشركة الخاصة نشاطها في أكثر من 100 دولة حول العالم، وتتخذ من مدينة نيويورك في الولايات المتحدة الأمريكية، مقراًرئيسياً لها. للمزيد من المعلومات، يرجى زيارة الموقع الإلكتروني: www.nielsen.com.
* نقوم بتقييم نتائج عملياتنا على أساس عملات متقلّبة وعملات ثابتة. ويعد تقديم العملات الثابتة، معياراً لمبادئ المحاسبة غير المعتمدة، ويستثني تأثير التقلبات في أسعار صرف العملات الأجنبية. ونعتقد أنّ تقديم معلومات ثابتة حول العملات يعطي معلومات إضافية ثمينة حول نتائج عملياتنا بطريقة تتوافق وتقييمنا لأدائنا. ونقوم باحتساب نسب العملات الثابتة المئوية عبر تحويل التتائج المالية للفترة السابقة بالعملة المحلية مستخدمين أسعار صرف الفترة الحالية لنقارن بعدها المبالغ المعدّلة مع نتائج تقريرنا الحالي.
نتائج العمليات – الأشهر الثلاثة المنتهية في 30 سبتمبر 2010 و2009
يظهر الجدول أدناه المبالغ الواردة في بيانات العمليات الموحّدة للأشهر الثلاثة المنتهية في 30 سبتمبر 2010 و2009:
الأشهر الثلاثة المنتهية في
30 سبتمبر
(حسابات غير مدقّقة)
(بملايين الدولارات)
2010
2009
الإيرادات
$
1,289
$
1,227
تكلفة الإيرادات، باستثناء الاهتلاك وانخفاض القيمة المبينة بشكل منفصل أدناه
521
521
تكاليف البيع الإدارية والعامة باستثناء الاهتلاكات وانخفاض القيمة المبينة بشكل منفصل أدناه
414
365
الاهتلاك وانخفاض القيمة
142
143
تراجع الشهرة التجارية والأصول غير الملموسة
-
527
تكاليف إعادة الهيكلة/(الائتمانات)
11
(3)
العائدات التشغيلية /(خسارة)
201
(326)
عائدات الفوائد
1
2
تكاليف الفوائد
(169
)
(168
)
الخسارة الناجمة عن الأدوات المالية المشتقة
(5
)
(21
)
صافي خسارة معاملات تبادل العملات الأجنبية معاملة
(5
)
(21 )
خسائر العمليات المستمرة قبل احتساب الضرائب على الدخل وصافي المساهمة في خسارة الشركات التابعة
23
(534
)
عائدات / مخصصات ضرائب على الدخل
(2)
99
المساهمة في الخسارة الصافية للشركات التابعة
1
(33
)
الخسائر من العمليات المستمرة
(22
)
(468
)
صافي العمليات الموقفة من دون حساب الضرائب
(11
)
(58
)
صافي الخسارة
(11
)
(526
)
صافي الدخل العائد الى فوائد غير مسيطرة
-
1
صافي خسارة شركة نيلسن بي في
$
(11
)
$
(527
)
نتائج العمليات – الأشهر التسعة المنتهية في 30 ديسمبر 2010 و2009:
يظهر الجدول أدناه المبالغ الواردة في بيانات العمليات الموحّدة للأشهر الثلاثة المنتهية في 30 سبتمبر 2010 و2009:
الأشهر الثلاثة المنتهية في
30 سبتمبر
(حسابات غير مدقّقة)
(بملايين الدولارات)
2010
2009
العائدات
$
3,755
$
3,511
تكلفة العائدات، باستثناء الاهتلاك وانخفاض القيمة المبينة بشكل منفصل أدناه
1,569
1,484
تكاليف البيع الإدارية والعامة باستثناء الاهتلاك وانخفاض القيمة المبينة بشكل منفصل أدناه
1,219
1,217
الاستهلاك والمستهلكات
419
409
تدهور السمعة التجارية والأصول غير الملموسة
-
527
تكاليف إعادة الهيكلة
33
6
إيرادات التشغيل/(الخسارة)
515
(42)
إيرادات الفوائد
3
6
تكاليف الفوائد
(491
)
(480
)
الخسارة الناجمة عن الأدوات المالية المشتقة
(17
)
(54
)
صافي خسارة معاملات تبادل العملات الأجنبية
دخل آخر/ (مصاريف)، صافية
140
9
10
(11)
خسائر العمليات المستمرة قبل احتساب الضرائب على الدخل وصافي المساهمة في خسارة الشركات التابعة
159
(571
)
عائدات / مخصصات ضرائب على الدخل
(14)
124
المساهمة في الخسارة الصافية للشركات التابعة
1
(25
)
الخسائر من العمليات المستمرة
146
(472
)
صافي العمليات الموقفة من دون حساب الضرائب
(19
)
(58
)
صافي الخسارة
127
(530
)
صافي الدخل العائد الى فوائد غير مسيطرة
1
2
صافي خسارة شركة نيلسن بي في
$
126
$
(532
)
ميثاق EBTIDA
يبيّن الجدول الآتي تسوية خسارتنا من العمليات المتواصلة، للأشهر الإثني عشرة المنتهية في 30 سبتمبر 2010، إلى ميثاق EBITDA كما محدّد أدناه بحسب التسهيلات الائتمانية الكبيرة المضمونة:
الأشهر الإثني عشرة المنتهية في
(بملايين الدولارات)
30 سبتمبر 2010
(غير مدققة)
الخسائر من العمليات المستمرة
$
191
صافي تكاليف الفوائد
651
عائدات ضرائب على الدخل
(57
)
الاهتلاك وانخفاض القيمة
567
الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة
1,352
الأعباء غير النقدية
18
بنود غير إعتيادية أو غير متكررة
80
تكاليف إعادة الهيكلة وتكاليف تحسين الأعمال
102
رسوم مراقبة الرعاة
12
أخرى
11
مبادئ الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة
$
1,415
ملاحظة: يدخل معيار الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة ضمن مبادئ المحاسبة غير المعتمدة، ويستخدم لتحديد مدى تطبيقنا لبعض المواثيق الواردة في التسهيلات الائتمانية الكبيرة المضمونة. وتم تعريف مبادئ الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة ضمن التسهيلات الائتمانية الكبيرة المضمونة كدخل صافٍ (خسارة) من العمليات المستمرة حسب الجدول أعلاه. ولا يعتبر معيار الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة عرضًا مقدّماً وفقًا لمبادئ المحاسبة المعتمدة، ويختلف استخدامنا لهذا المعيار عن غيرنا قي القطاع نظرًا للتضاربات المحتملة في طريقة الاحتساب والاختلاف بالمواد التي قد تخضع للتأويل. ولا يجب اعتبار هذا المعيار بديلاً عن الدخل الصافي (الخسارة) ودخل التشغيل أو أي معايير قياس أخرى مشتقة وفقًا لمبادئ المحاسبة المعتمدة كمعايير قياس أداء التشغيل أو تدفق النقد كمعيار قياس السيولة.
ولمعيار الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة قيود مهمة كونه أداة تحليلية ولا يجوز اعتباره لوحده أو كبديل لتحاليل نتائجنا بتقرير بموجب مبادئ المحاسبة المعتمدة. وعلى سبيل المثال، فإن هذا المعيار:
· لا يتضمن مدفوعات ضريبة الدخل ؛
* لا يعكس أي متطلبات نقدية لمصاريف رأس المال ؛
* لا يعكس التغيرات في، أو الاحتياجات النقدية لاحتياجات رأس المال العامل؛
* لا يعكس الإنفاق الكبير على الفوائد أو الاحتياجات النقدية اللازمة لخدمة فوائد أو مدفوعات أصل الدين؛
* لا يعكس الرسوم الإدارية التي تدفع إلى الرعاة؛
* لا يعكس تأثير الأرباح أو الأعباء الناجمة عن المسائل التي لا نعتبرها مؤشراً علينا على عملياتنا الجارية حاليا نحن وكبار المقرضين في إطار التسهيلات الائتمانية الكبيرة المضمونة.
وبشكل خاص، يسمح لنا تحديد معيار الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة بإضافة بعض التكاليف غير النقدية وغير المتكررة التي لا تحتسب عند احتساب الدخل الصافي. لكن هذه التكاليف التي قد تتكرر تختلف بشكل كبير ويصعب توقّعها. ويمكنها تمثيل أثر الاستراتيجيات طويلة الأجل مقارنة مع النتائج على المدى القصير. وإضافة إلى ذلك، قد تمثّل بعض هذه التكاليف حداً من الأموال النقدية التي يمكن استخدامها لأغراض أخرى للشركة.
نظرًا لهذه القيود، نعتمد بالدرجة الأولى على نتائج مبادئ المحاسبة المعتمدة، إلا أنّنا نعتقد أنّ إدخال التعديلات الإضافية على الأرباح قبل الفوائد والضرائب والاهتلاك وانخفاض القيمة المطبّقة عند تقديم المعيار، يعد أمراً مناسباً لمنح المستثمرين معلومات إضافية لإظهار التوافق مع اتفاقياتنا المالية.
إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.
لاستفسارات الإعلام، الرجاء الاتصال بـِ:
شركة "نيلسن بي في"
علاقات الاستثمار
ريتش نيلسن
هاتف: 7761-654-646-1+
علاقات إعلامية:
إد داندريدج
هاتف: 8656-654-646-1+
Monday, November 1, 2010
UTOPIA Announces Successful Testing for Its Luxury Ship
SEOUL, South Korea, Monday, November 1st 2010 [ME NewsWire]:
(BUSINESS WIRE)-- UTOPIA announced the completion of successful testing of the hull and propellers for its US$1.1 billion residential ship – The UTOPIA. The vessel will be the most luxurious ship in the world. Its 200 residents will be able to travel to world famous cultural and sporting events in opulent style.
The Chairman of UTOPIA Mr. David Robb said “This is a technological breakthrough. We have completed the core technical testing for this luxurious ocean liner. The ship’s hull will be wider than hulls on most passenger vessels, which will give our residents on this ocean liner smoother sailing. The hull was also modified to be more environmentally friendly. As a result, we have a more fuel efficient hull and propellers that will move through the ocean more quietly and sensitively.”
The President of Samsung Heavy Industries Mr. Roh In-Sik remarked “This is a significant event in the building of UTOPIA and a significant milestone for Samsung as we further penetrate the passenger ship market internationally. With this investment in The UTOPIA, we come closer to producing the world’s most luxurious ship.”
For several months, engineering teams from Samsung and UTOPIA worked together in Korea where Samsung owns the largest commercial hull testing facility in the world (SSMB). The final tests have just concluded successfully.
Samsung President Mr. Roh In-Sik also remarked “Samsung selected its best engineers companywide for The UTOPIA. There are over 70 engineers and technical personnel working on The UTOPIA.”
Captain Ola Harsheim, the UTOPIA Vice President of shipbuilding commented “The successful completion of these hull tests has proven the technical viability of our ship. These tests go way beyond any computer model or simulations because they are physical tests on water. The completion of these tests is very exciting for our resident community. The widening of The UTOPIA hull and the inclusion of four stabilizers make our ship unique and will maximize the comfort for our residents and guests.”
Photographs of the hull testing are available for viewing at UTOPIA’s Rodeo Drive showroom in Beverly Hills at 421 North Rodeo Drive, Beverly Hills, California, USA
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6491088&lang=en
For media enquiries, please contact:
UTOPIA
UTOPIA International Media Relations:
Media Relations Department (day or night), +1-315-294-5031
Jason LeGaspe or Sheila Xia, +1-310-270-4777
UTOPIA Website:
www.utopiaresidences.com
(BUSINESS WIRE)-- UTOPIA announced the completion of successful testing of the hull and propellers for its US$1.1 billion residential ship – The UTOPIA. The vessel will be the most luxurious ship in the world. Its 200 residents will be able to travel to world famous cultural and sporting events in opulent style.
The Chairman of UTOPIA Mr. David Robb said “This is a technological breakthrough. We have completed the core technical testing for this luxurious ocean liner. The ship’s hull will be wider than hulls on most passenger vessels, which will give our residents on this ocean liner smoother sailing. The hull was also modified to be more environmentally friendly. As a result, we have a more fuel efficient hull and propellers that will move through the ocean more quietly and sensitively.”
The President of Samsung Heavy Industries Mr. Roh In-Sik remarked “This is a significant event in the building of UTOPIA and a significant milestone for Samsung as we further penetrate the passenger ship market internationally. With this investment in The UTOPIA, we come closer to producing the world’s most luxurious ship.”
For several months, engineering teams from Samsung and UTOPIA worked together in Korea where Samsung owns the largest commercial hull testing facility in the world (SSMB). The final tests have just concluded successfully.
Samsung President Mr. Roh In-Sik also remarked “Samsung selected its best engineers companywide for The UTOPIA. There are over 70 engineers and technical personnel working on The UTOPIA.”
Captain Ola Harsheim, the UTOPIA Vice President of shipbuilding commented “The successful completion of these hull tests has proven the technical viability of our ship. These tests go way beyond any computer model or simulations because they are physical tests on water. The completion of these tests is very exciting for our resident community. The widening of The UTOPIA hull and the inclusion of four stabilizers make our ship unique and will maximize the comfort for our residents and guests.”
Photographs of the hull testing are available for viewing at UTOPIA’s Rodeo Drive showroom in Beverly Hills at 421 North Rodeo Drive, Beverly Hills, California, USA
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6491088&lang=en
For media enquiries, please contact:
UTOPIA
UTOPIA International Media Relations:
Media Relations Department (day or night), +1-315-294-5031
Jason LeGaspe or Sheila Xia, +1-310-270-4777
UTOPIA Website:
www.utopiaresidences.com
Al Maha Desert Resort and Spa Joins Starwood Hotels and Resorts’ Middle East Portfolio
Under Strategic Agreement with Emirates Group, Award-Winning Hotel Becomes Al Maha, a Luxury Collection Desert Resort and Spa
Dubai, United Arab Emirates, Monday, November 1st 2010 [ME NewsWire]:
(BUSINESS WIRE)-- Al Maha Desert Resort and Spa in Dubai will join Starwood Hotels and Resorts Worldwide Inc. as the latest addition to its Luxury Collection portfolio, effective today. The hotel will be renamed ‘Al Maha, a Luxury Collection Desert Resort and Spa, Dubai’, with Emirates retaining ownership of the resort and Starwood Hotels and Resorts overseeing the management of the property.
Designed and built following the principles of environmentally friendly development, Al Maha has been at the forefront of eco tourism in the Middle East for over 10 years. The resort was designed to recreate a Bedouin encampment spread across the vast dunes, featuring 42 secluded suites with tented roofs, floor-to-ceiling windows, marbled bathrooms, private deck and pool.
“A pioneer in the area of luxury conservation-based hospitality in the Middle East, Al Maha will be a valuable addition to The Luxury Collection,” said His Highness Sheikh Ahmed bin Saeed Al-Maktoum, Chairman and Chief Executive, Emirates Airline & Group. “As a leading hotel management group, Starwood’s Luxury Collection brand represents some of the finest properties across the world, and with their extensive network, global infrastructure and history of successful brand management, we are confident that they will take Al Maha to even greater heights.”
“We are delighted to take over the management of the Al Maha Resort, extending our long-standing relationship with the Emirates Group and adding a spectacular hotel to the Luxury Collection portfolio in Dubai,” stated Roeland Vos, President of Starwood, Europe, Africa and Middle East. “The addition of the Al Maha Desert Resort and Spa is symbolic of our continued focus to grow our portfolio of luxury hotels and resorts in the Middle East.”
Al Maha rests within the 225-square kilometre Dubai Desert Conservation Reserve (DDCR), one of the largest formally protected conservation reserves in the Gulf, and is internationally recognised. The DDCR will continue to be sponsored and managed by Emirates. Al Maha was lauded for its efforts by the World Travel and Tourism Council earlier this year and was identified as the region’s leading sustainable eco-tourism development by the United Nations Environment Programme (UNEP).
Surrounded by some of the region’s most spectacular landscape, rich with protected wildlife and filled with experiences of traditional Bedouin pastimes, Al Maha offers a sophisticated, yet simple and serene experience to its guests. Sunset camel rides, desert safaris, wildlife drives, horse-riding and falconry are all part of the unique indigenous experience at the resort as well as soothing massage treatments at its spa with an infinity pool overlooking the sands, scrub and mountains.
A discrete suite of meeting rooms is available for small boardroom and executive conferences and the resort has been acclaimed as the ultimate incentive destination.
In addition, the Al Maha Desert Resort and Spa has taken on the mantle of a cultural treasure trove. Its initial collection of Arab antiques, artefacts and artworks acquired to fuel the Arabic experience in suites and public areas now expanded to more than 2,000 pieces covering carpets, tents, jewellery, brass coffee pots, camel bags and saddles as well as specially commissioned wildlife paintings.
The Al Maha Desert Resort and Spa is Starwood’s second Luxury Collection hotel in the UAE, joining the iconic Grosvenor House Dubai, and third in the Middle East. Starwood Hotels and Resorts currently operates more than 50 hotels in the Middle East under eight of the company’s nine brands including: The Luxury Collection, St. Regis, Sheraton, Westin, W Hotels, Le Méridien, Four Points by Sheraton and Aloft. The company has plans to open additional luxury hotels under its Luxury Collection and St. Regis brands in the following destinations: Doha (Qatar), Abu Dhabi, Ajman, and Dubai (UAE), Aqaba (Jordan) and Manama (Bahrain).
About The Luxury Collection Hotels & Resorts
The Luxury Collection® is an ensemble of hotels and resorts offering unique, authentic experiences that evoke lasting, treasured memories. For the global explorer, The Luxury Collection offers a gateway to the world’s most exciting and desirable destinations. Each hotel and resort is a unique and cherished expression of its location; a portal to the destination’s indigenous charms and treasures. Magnificent décor, spectacular settings, impeccable service and the latest modern conveniences combine to provide a uniquely enriching experience.
Originated in 1906 under the CIGA brand as a collection of Europe’s most celebrated and iconic properties, today The Luxury Collection brand is a glittering ensemble of more than 75 of the world’s finest hotels and resorts in more than 30 countries in bustling cities and spectacular destinations around the world. The Luxury Collection includes award-winning properties that continuously exceed guest expectations by offering unparalleled service, style and class while celebrating each hotel’s distinctive heritage and unique character. All of these hotels, many of them centuries old, are internationally recognized as being among the world’s finest. For more information, please visit www.luxurycollection.com.
About Emirates
Dubai-based Emirates Airline, one of the fastest growing airlines in the world, has received more than 400 international awards for excellence. Emirates now flies to 108 destinations in 65 countries in Europe, North America, South America, the Middle East, Africa, the Indian subcontinent and Asia-Pacific. Emirates operates 153 wide-body Airbus and Boeing aircraft, with a fleet that is among the youngest in the skies, an average age of 69 months. With orders for an additional 200 aircraft, worth more than USD$59 billion, Emirates is on track to become one of the largest airlines in the world. The airline reported a net profit of USD$964 million for the last fiscal year. For more information please visit www.emirates.com.
For media enquiries, please contact:
Starwood Hotels & Resorts, Europe, Africa and Middle East (Media):
Jenni Benzaquen, Director Public Relations
+32 (0)2 204 5494
jenni.benzaquen@starwoodhotels.com
Emirates Corporate Communications (Media):
Smita Natalia Deans / Maria Elena Alba
P: (+9714) 708 4470 / 3976 -
M: (+9715 6) 684 8972 / (+9715 0) 950 9630
smita.deans@emirates.com -
maria.elena@emirates.com
Dubai, United Arab Emirates, Monday, November 1st 2010 [ME NewsWire]:
(BUSINESS WIRE)-- Al Maha Desert Resort and Spa in Dubai will join Starwood Hotels and Resorts Worldwide Inc. as the latest addition to its Luxury Collection portfolio, effective today. The hotel will be renamed ‘Al Maha, a Luxury Collection Desert Resort and Spa, Dubai’, with Emirates retaining ownership of the resort and Starwood Hotels and Resorts overseeing the management of the property.
Designed and built following the principles of environmentally friendly development, Al Maha has been at the forefront of eco tourism in the Middle East for over 10 years. The resort was designed to recreate a Bedouin encampment spread across the vast dunes, featuring 42 secluded suites with tented roofs, floor-to-ceiling windows, marbled bathrooms, private deck and pool.
“A pioneer in the area of luxury conservation-based hospitality in the Middle East, Al Maha will be a valuable addition to The Luxury Collection,” said His Highness Sheikh Ahmed bin Saeed Al-Maktoum, Chairman and Chief Executive, Emirates Airline & Group. “As a leading hotel management group, Starwood’s Luxury Collection brand represents some of the finest properties across the world, and with their extensive network, global infrastructure and history of successful brand management, we are confident that they will take Al Maha to even greater heights.”
“We are delighted to take over the management of the Al Maha Resort, extending our long-standing relationship with the Emirates Group and adding a spectacular hotel to the Luxury Collection portfolio in Dubai,” stated Roeland Vos, President of Starwood, Europe, Africa and Middle East. “The addition of the Al Maha Desert Resort and Spa is symbolic of our continued focus to grow our portfolio of luxury hotels and resorts in the Middle East.”
Al Maha rests within the 225-square kilometre Dubai Desert Conservation Reserve (DDCR), one of the largest formally protected conservation reserves in the Gulf, and is internationally recognised. The DDCR will continue to be sponsored and managed by Emirates. Al Maha was lauded for its efforts by the World Travel and Tourism Council earlier this year and was identified as the region’s leading sustainable eco-tourism development by the United Nations Environment Programme (UNEP).
Surrounded by some of the region’s most spectacular landscape, rich with protected wildlife and filled with experiences of traditional Bedouin pastimes, Al Maha offers a sophisticated, yet simple and serene experience to its guests. Sunset camel rides, desert safaris, wildlife drives, horse-riding and falconry are all part of the unique indigenous experience at the resort as well as soothing massage treatments at its spa with an infinity pool overlooking the sands, scrub and mountains.
A discrete suite of meeting rooms is available for small boardroom and executive conferences and the resort has been acclaimed as the ultimate incentive destination.
In addition, the Al Maha Desert Resort and Spa has taken on the mantle of a cultural treasure trove. Its initial collection of Arab antiques, artefacts and artworks acquired to fuel the Arabic experience in suites and public areas now expanded to more than 2,000 pieces covering carpets, tents, jewellery, brass coffee pots, camel bags and saddles as well as specially commissioned wildlife paintings.
The Al Maha Desert Resort and Spa is Starwood’s second Luxury Collection hotel in the UAE, joining the iconic Grosvenor House Dubai, and third in the Middle East. Starwood Hotels and Resorts currently operates more than 50 hotels in the Middle East under eight of the company’s nine brands including: The Luxury Collection, St. Regis, Sheraton, Westin, W Hotels, Le Méridien, Four Points by Sheraton and Aloft. The company has plans to open additional luxury hotels under its Luxury Collection and St. Regis brands in the following destinations: Doha (Qatar), Abu Dhabi, Ajman, and Dubai (UAE), Aqaba (Jordan) and Manama (Bahrain).
About The Luxury Collection Hotels & Resorts
The Luxury Collection® is an ensemble of hotels and resorts offering unique, authentic experiences that evoke lasting, treasured memories. For the global explorer, The Luxury Collection offers a gateway to the world’s most exciting and desirable destinations. Each hotel and resort is a unique and cherished expression of its location; a portal to the destination’s indigenous charms and treasures. Magnificent décor, spectacular settings, impeccable service and the latest modern conveniences combine to provide a uniquely enriching experience.
Originated in 1906 under the CIGA brand as a collection of Europe’s most celebrated and iconic properties, today The Luxury Collection brand is a glittering ensemble of more than 75 of the world’s finest hotels and resorts in more than 30 countries in bustling cities and spectacular destinations around the world. The Luxury Collection includes award-winning properties that continuously exceed guest expectations by offering unparalleled service, style and class while celebrating each hotel’s distinctive heritage and unique character. All of these hotels, many of them centuries old, are internationally recognized as being among the world’s finest. For more information, please visit www.luxurycollection.com.
About Emirates
Dubai-based Emirates Airline, one of the fastest growing airlines in the world, has received more than 400 international awards for excellence. Emirates now flies to 108 destinations in 65 countries in Europe, North America, South America, the Middle East, Africa, the Indian subcontinent and Asia-Pacific. Emirates operates 153 wide-body Airbus and Boeing aircraft, with a fleet that is among the youngest in the skies, an average age of 69 months. With orders for an additional 200 aircraft, worth more than USD$59 billion, Emirates is on track to become one of the largest airlines in the world. The airline reported a net profit of USD$964 million for the last fiscal year. For more information please visit www.emirates.com.
For media enquiries, please contact:
Starwood Hotels & Resorts, Europe, Africa and Middle East (Media):
Jenni Benzaquen, Director Public Relations
+32 (0)2 204 5494
jenni.benzaquen@starwoodhotels.com
Emirates Corporate Communications (Media):
Smita Natalia Deans / Maria Elena Alba
P: (+9714) 708 4470 / 3976 -
M: (+9715 6) 684 8972 / (+9715 0) 950 9630
smita.deans@emirates.com -
maria.elena@emirates.com
Celgene Reports Record Third Quarter 2010 Operating and Financial Results
SUMMIT, N.J., Sunday, October 31st 2010 [ME NewsWire]:
Record Third Quarter Results Driven By Share Gains Across Major Markets
REVLIMID® Third Quarter Global Net Product Sales Increased 43% Y/Y
VIDAZA® Third Quarter Global Net Product Sales Increased 37% Y/Y
Non-GAAP Third Quarter Diluted Earnings Per Share Increased 34% Y/Y
(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG):
2010 Third Quarter Financial Results Year-Over-Year
* Non-GAAP Total Revenue Increased 31 Percent to $908 Million; GAAP Total Revenue $910 Million
* Global REVLIMID Net Product Sales Increased 43 Percent to $641 Million
* Global VIDAZA Net Product Sales Increased 37 Percent to $141 Million
* Global THALOMID® Net Product Sales of $94 Million
* Non-GAAP Operating Income Increased 40 Percent to $409 Million; GAAP Operating Income $311 Million
* Non-GAAP Net Income Increased 35 Percent to $350 Million; GAAP Net Income $281 Million
* Non-GAAP Diluted Earnings Per Share Increased 34 Percent to $0.75; GAAP Diluted Earnings Per Share $0.60
2010 Financial Outlook Update (Includes Impact of Acquisition of Abraxis BioScience)
* Total Revenue Expected to Increase Approximately 34 Percent Year-Over-Year to Approximately $3.60 Billion, Up From a Previous Range of $3.40 to $3.45 Billion
* REVLIMID Net Product Sales Anticipated to Increase Approximately 44 Percent Year-Over-Year to Approximately $2.45 Billion, Up From a Previous Range of $2.30 to $2.35 Billion
* Non-GAAP Diluted Earnings Per Share Expected to Increase Approximately 34 Percent Year-Over-Year to a Range of $2.78 to $2.80, Up From a Previous Range of $2.65 to $2.70
Recent Developments and Highlights
* Completed Acquisition of Abraxis BioScience
* Completed $1.25 Billion Debut Debt Offering
* Announced Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer
* Initiated Launch of REVLIMID® in Japan for Treatment of Relapsed/Refractory Multiple Myeloma
* Initiated PALACE 1, PALACE 2, and PALACE 3, Phase III Trials Evaluating Apremilast in Psoriatic Arthritis, and ESTEEM 1, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis
* Brought Infringement Action to Enforce our REVLIMID Patents Against Natco Pharma Ltd. for Filing an Abbreviated New Drug Application With a Paragraph IV Certification for Lenalidomide
* ABRAXANE® Pharmaceutical Composition and Method Claims Patent Issued on October 26, 2010, expiring in 2024
* Initiated MF-002, a Phase III Trial Evaluating Pomalidomide in Myelofibrosis
* Initiated AZA-AML-001, a Phase III Trial Evaluating VIDAZA® in Newly Diagnosed Acute Myeloid Leukemia
* Initiated Phase II Trial for PDA-001 Cellular Therapy in Crohn’s Disease
2010 Selected Corporate Objectives
* Expand Celgene Product Approvals, Reimbursements, and Global Market Share
* Submit REVLIMID Newly Diagnosed Multiple Myeloma (NDMM) Regulatory Filing with European Medicines Agency
* Complete Enrollment of MM-020, a Phase III Trial Evaluating REVLIMID and Low-Dose Dexamethasone Versus Melphalan, Prednisone, and Thalidomide in NDMM
* Submit ISTODAX® Peripheral T-cell Lymphoma Regulatory Filing with Food and Drug Administration
* Advance More Than 25 Phase III and Pivotal Clinical Trials and 17 Preclinical Programs Addressing More Than 30 Serious and Debilitating Diseases
* Initiate ESTEEM 2, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis, and PALACE 4, a Phase III Trial Evaluating Apremilast in Psoriatic Arthritis
* Initiate Phase II Trial for Apremilast in Rheumatoid Arthritis
* Initiate Phase II Trial for PDA-001 Cellular Therapy in Ischemic Stroke; Initiate Phase I Trial in Multiple Sclerosis
* Initiate Phase II Trial for JNK CC-930 in Idiopathic Pulmonary Fibrosis and Discoid Lupus Erythematosus
Celgene Corporation (NASDAQ: CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010. Non-GAAP net income for the third quarter of 2009 was $259.8 million or non-GAAP diluted earnings per share of $0.56. Based on U.S. GAAP, Celgene reported net income of $281.2 million, or diluted earnings per share of $0.60 for the quarter ended September 30, 2010. GAAP net income for the third quarter of 2009 was $216.8 million, or diluted earnings per share of $0.46.
Celgene posted non-GAAP net income of $967.7 million or non-GAAP diluted earnings per share of $2.07 during the first nine months of 2010 as compared to non-GAAP net income of $681.0 million and non-GAAP diluted earnings per share of $1.46 in 2009. On a GAAP basis, Celgene reported net income of $670.9 million, or diluted earnings per share of $1.44 for the first nine months of 2010, compared to GAAP net income of $522.5 million, or diluted earnings per share of $1.12 in 2009.
“Our third quarter results reflect outstanding operational execution by our global team,” said Bob Hugin, Celgene’s Chief Executive Officer. “Our expanding portfolio of innovative therapies in oncology and immune-inflammatory diseases further positions us for sustained growth and value creation in the near and long term.”
Product Sales Performance
Non-GAAP total revenue was a record $908.1 million for the quarter ended September 30, 2010, an increase of 31 percent from 2009. GAAP total revenue was $910.1 million for the quarter ended September 30, 2010. The increase in total revenue was driven by global market share gains and increased duration of therapy of REVLIMID® and VIDAZA®. Net sales of REVLIMID were $641.3 million, an increase of 43 percent over the same period in 2009. VIDAZA® net sales were $141.4 million, an increase of 37 percent from 2009. Global THALOMID® (inclusive of Thalidomide Celgene® and Thalidomide Pharmion®) sales were $94.2 million, a 14 percent decrease from 2009. Revenue from Focalin® and the Ritalin® family of drugs totaled $22.6 million for the third quarter of 2010 compared to $25.8 million over the same period in 2009.
For the first nine months of 2010, non-GAAP total revenue was a record $2.547 billion, an increase of 33 percent year-over-year. GAAP total revenue was $2.554 billion for the nine months ended September 30, 2010. REVLIMID net sales for the first nine months of 2010 were $1.759 billion, an increase of 45 percent over $1.209 billion for the same period in 2009. VIDAZA net sales for the first nine months of 2010 were $393.6 million, an increase of 46 percent over the same period in 2009. THALOMID net sales for the first nine months of 2010 were $296.0 million, a decrease of 10 percent from the same period in 2009. Revenue from Focalin and the Ritalin family of drugs totaled $79.3 million for the first nine months of 2010, an increase of 3 percent over the same period in 2009.
Research and Development
For the third quarter of 2010, non-GAAP R&D expenses, which exclude upfront collaboration payments and share-based employee compensation expense, were $232.3 million compared to $178.2 million for the third quarter of 2009. These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID, pomalidomide, and other compounds; VIDAZA; ISTODAX®; amrubicin; apremilast and our oral anti-inflammatory compounds; our kinase inhibitor programs; our activin inhibitor program with ACE-011; and cellular therapy programs. On a GAAP basis, R&D expenses were $253.5 million for the third quarter of 2010 and $193.4 million in the same period in 2009.
Click here for full press release including tables.
For media enquiries, please contact:
Celgene Corporation
Jacqualyn A. Fouse, 908-673-9956
Sr. Vice President and Chief Financial Officer
Tim Smith, 908-673-9951
Director, Investor Relations
Record Third Quarter Results Driven By Share Gains Across Major Markets
REVLIMID® Third Quarter Global Net Product Sales Increased 43% Y/Y
VIDAZA® Third Quarter Global Net Product Sales Increased 37% Y/Y
Non-GAAP Third Quarter Diluted Earnings Per Share Increased 34% Y/Y
(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG):
2010 Third Quarter Financial Results Year-Over-Year
* Non-GAAP Total Revenue Increased 31 Percent to $908 Million; GAAP Total Revenue $910 Million
* Global REVLIMID Net Product Sales Increased 43 Percent to $641 Million
* Global VIDAZA Net Product Sales Increased 37 Percent to $141 Million
* Global THALOMID® Net Product Sales of $94 Million
* Non-GAAP Operating Income Increased 40 Percent to $409 Million; GAAP Operating Income $311 Million
* Non-GAAP Net Income Increased 35 Percent to $350 Million; GAAP Net Income $281 Million
* Non-GAAP Diluted Earnings Per Share Increased 34 Percent to $0.75; GAAP Diluted Earnings Per Share $0.60
2010 Financial Outlook Update (Includes Impact of Acquisition of Abraxis BioScience)
* Total Revenue Expected to Increase Approximately 34 Percent Year-Over-Year to Approximately $3.60 Billion, Up From a Previous Range of $3.40 to $3.45 Billion
* REVLIMID Net Product Sales Anticipated to Increase Approximately 44 Percent Year-Over-Year to Approximately $2.45 Billion, Up From a Previous Range of $2.30 to $2.35 Billion
* Non-GAAP Diluted Earnings Per Share Expected to Increase Approximately 34 Percent Year-Over-Year to a Range of $2.78 to $2.80, Up From a Previous Range of $2.65 to $2.70
Recent Developments and Highlights
* Completed Acquisition of Abraxis BioScience
* Completed $1.25 Billion Debut Debt Offering
* Announced Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer
* Initiated Launch of REVLIMID® in Japan for Treatment of Relapsed/Refractory Multiple Myeloma
* Initiated PALACE 1, PALACE 2, and PALACE 3, Phase III Trials Evaluating Apremilast in Psoriatic Arthritis, and ESTEEM 1, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis
* Brought Infringement Action to Enforce our REVLIMID Patents Against Natco Pharma Ltd. for Filing an Abbreviated New Drug Application With a Paragraph IV Certification for Lenalidomide
* ABRAXANE® Pharmaceutical Composition and Method Claims Patent Issued on October 26, 2010, expiring in 2024
* Initiated MF-002, a Phase III Trial Evaluating Pomalidomide in Myelofibrosis
* Initiated AZA-AML-001, a Phase III Trial Evaluating VIDAZA® in Newly Diagnosed Acute Myeloid Leukemia
* Initiated Phase II Trial for PDA-001 Cellular Therapy in Crohn’s Disease
2010 Selected Corporate Objectives
* Expand Celgene Product Approvals, Reimbursements, and Global Market Share
* Submit REVLIMID Newly Diagnosed Multiple Myeloma (NDMM) Regulatory Filing with European Medicines Agency
* Complete Enrollment of MM-020, a Phase III Trial Evaluating REVLIMID and Low-Dose Dexamethasone Versus Melphalan, Prednisone, and Thalidomide in NDMM
* Submit ISTODAX® Peripheral T-cell Lymphoma Regulatory Filing with Food and Drug Administration
* Advance More Than 25 Phase III and Pivotal Clinical Trials and 17 Preclinical Programs Addressing More Than 30 Serious and Debilitating Diseases
* Initiate ESTEEM 2, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis, and PALACE 4, a Phase III Trial Evaluating Apremilast in Psoriatic Arthritis
* Initiate Phase II Trial for Apremilast in Rheumatoid Arthritis
* Initiate Phase II Trial for PDA-001 Cellular Therapy in Ischemic Stroke; Initiate Phase I Trial in Multiple Sclerosis
* Initiate Phase II Trial for JNK CC-930 in Idiopathic Pulmonary Fibrosis and Discoid Lupus Erythematosus
Celgene Corporation (NASDAQ: CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010. Non-GAAP net income for the third quarter of 2009 was $259.8 million or non-GAAP diluted earnings per share of $0.56. Based on U.S. GAAP, Celgene reported net income of $281.2 million, or diluted earnings per share of $0.60 for the quarter ended September 30, 2010. GAAP net income for the third quarter of 2009 was $216.8 million, or diluted earnings per share of $0.46.
Celgene posted non-GAAP net income of $967.7 million or non-GAAP diluted earnings per share of $2.07 during the first nine months of 2010 as compared to non-GAAP net income of $681.0 million and non-GAAP diluted earnings per share of $1.46 in 2009. On a GAAP basis, Celgene reported net income of $670.9 million, or diluted earnings per share of $1.44 for the first nine months of 2010, compared to GAAP net income of $522.5 million, or diluted earnings per share of $1.12 in 2009.
“Our third quarter results reflect outstanding operational execution by our global team,” said Bob Hugin, Celgene’s Chief Executive Officer. “Our expanding portfolio of innovative therapies in oncology and immune-inflammatory diseases further positions us for sustained growth and value creation in the near and long term.”
Product Sales Performance
Non-GAAP total revenue was a record $908.1 million for the quarter ended September 30, 2010, an increase of 31 percent from 2009. GAAP total revenue was $910.1 million for the quarter ended September 30, 2010. The increase in total revenue was driven by global market share gains and increased duration of therapy of REVLIMID® and VIDAZA®. Net sales of REVLIMID were $641.3 million, an increase of 43 percent over the same period in 2009. VIDAZA® net sales were $141.4 million, an increase of 37 percent from 2009. Global THALOMID® (inclusive of Thalidomide Celgene® and Thalidomide Pharmion®) sales were $94.2 million, a 14 percent decrease from 2009. Revenue from Focalin® and the Ritalin® family of drugs totaled $22.6 million for the third quarter of 2010 compared to $25.8 million over the same period in 2009.
For the first nine months of 2010, non-GAAP total revenue was a record $2.547 billion, an increase of 33 percent year-over-year. GAAP total revenue was $2.554 billion for the nine months ended September 30, 2010. REVLIMID net sales for the first nine months of 2010 were $1.759 billion, an increase of 45 percent over $1.209 billion for the same period in 2009. VIDAZA net sales for the first nine months of 2010 were $393.6 million, an increase of 46 percent over the same period in 2009. THALOMID net sales for the first nine months of 2010 were $296.0 million, a decrease of 10 percent from the same period in 2009. Revenue from Focalin and the Ritalin family of drugs totaled $79.3 million for the first nine months of 2010, an increase of 3 percent over the same period in 2009.
Research and Development
For the third quarter of 2010, non-GAAP R&D expenses, which exclude upfront collaboration payments and share-based employee compensation expense, were $232.3 million compared to $178.2 million for the third quarter of 2009. These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID, pomalidomide, and other compounds; VIDAZA; ISTODAX®; amrubicin; apremilast and our oral anti-inflammatory compounds; our kinase inhibitor programs; our activin inhibitor program with ACE-011; and cellular therapy programs. On a GAAP basis, R&D expenses were $253.5 million for the third quarter of 2010 and $193.4 million in the same period in 2009.
Click here for full press release including tables.
For media enquiries, please contact:
Celgene Corporation
Jacqualyn A. Fouse, 908-673-9956
Sr. Vice President and Chief Financial Officer
Tim Smith, 908-673-9951
Director, Investor Relations
Etisalat named ‘Best Telecom Operator’ in MENASA region
Abu Dhabi; UAE, Sunday, October 31st 2010 [ME NewsWire]:
* Wins four top honours at SAMENA Telecommunication Council Awards
* Mohammad Omran honoured as ‘Best Telecom Operator Leader’
* Awards highlight Etisalat’s competencies and reach in the world’s fastest growing regions.
Etisalat, the leading telecom operator with a presence in 18 countries, has been named as the ‘Best Telecom Operator’ in the Middle East, North Africa and South Asia (MENASA) region, a wide geographic market that covers nearly 30 per cent of the world population.
Trumping competition from fast-growing telecom markets with several operators, Etisalat won four top laurels at the recent SAMENA Telecommunications Council Awards that honoured the best in telecom industry services, across the geographies including the Middle East, North Africa and South Asia.
Selected following an intensive performance-based evaluation of telecom operators across the region, Etisalat also won the awards for Best Customer Experience Provider of the Year and Best FMC Operator of the Year, while the company’s chairman, Mohammad Omran, was selected as Best Telecom Operator Leader of the Year. The award recognised his pioneering efforts in leading Etisalat’s achievements regionally and globally, and for his efforts in significantly strengthening the telecom sector across the Middle East, Africa and Asia.
The SAMENA Awards were distributed at a ceremony held in Morocco recently as part of the ‘Converge to Casablanca 2010’ conference which highlighted the importance of the convergence of industry leaders to discuss key technology areas.
Bocar A. Ba, President of SAMENA Telecommunications Council said, “Etisalat has always been an active participant and keen supporter of various efforts in promoting collaborative solutions and knowledge-sharing within the telecommunications industry. As a leading operator, Etisalat has been at the forefront of a number of innovative solutions and services, and has contributed enormously to the growth and advancement of the sector locally and regionally. It is indeed great to see the organization winning four SAMENA awards in recognition of their constant efforts to further develop and promote the regional telecommunications industry and provide seamless services to their customers. I would also like to extend my warm congratulations to the Chairman on his selection as the ’Best Outstanding Telecom Operator Leader’ of the year.”
SAMENA Telecommunications Council is a multi-continent telecom consortium that aims to be the leading provider of telecom innovations in its member regions as well as a facilitator for collaboration and knowledge-sharing between regional telecom entities.
The SAMENA Awards demonstrate Etisalat’s ongoing efforts in the development of the telecommunications sector in the UAE and beyond, in terms of infrastructure and advanced telecommunications, which are critical foundations for economic success. The awards recognize Etisalat’s innovations and strategies in customer service which focus on applying the latest systems and emphasis on achieving the highest standards in customer satisfaction.
As a leader in offering the latest services to all residents of the UAE, Etisalat covers 100% of GSM network coverage across UAE and 99% 3G coverage of UAE's populated areas.
Etisalat operates in 18 countries across Asia, the Middle East and Africa, servicing over 107 million customers out of a total population of approximately 2 billion people.
Etisalat is a major investor in Thuraya, one of the world’s leading satellite geo-mobile communication systems covering approximately two thirds of the planet’s surface. The company is also the largest carrier for voice data in the Middle East, and has the largest roaming network in the region with 600 agreements that cover more than 190 countries worldwide.
For media enquiries, please contact:
Iyad AlZoubi,
Senior Manager International Media Relations, Etisalat
Tel: 02 6182173
Fax: 02 6334448
ialzoubi@etisalat.ae
* Wins four top honours at SAMENA Telecommunication Council Awards
* Mohammad Omran honoured as ‘Best Telecom Operator Leader’
* Awards highlight Etisalat’s competencies and reach in the world’s fastest growing regions.
Etisalat, the leading telecom operator with a presence in 18 countries, has been named as the ‘Best Telecom Operator’ in the Middle East, North Africa and South Asia (MENASA) region, a wide geographic market that covers nearly 30 per cent of the world population.
Trumping competition from fast-growing telecom markets with several operators, Etisalat won four top laurels at the recent SAMENA Telecommunications Council Awards that honoured the best in telecom industry services, across the geographies including the Middle East, North Africa and South Asia.
Selected following an intensive performance-based evaluation of telecom operators across the region, Etisalat also won the awards for Best Customer Experience Provider of the Year and Best FMC Operator of the Year, while the company’s chairman, Mohammad Omran, was selected as Best Telecom Operator Leader of the Year. The award recognised his pioneering efforts in leading Etisalat’s achievements regionally and globally, and for his efforts in significantly strengthening the telecom sector across the Middle East, Africa and Asia.
The SAMENA Awards were distributed at a ceremony held in Morocco recently as part of the ‘Converge to Casablanca 2010’ conference which highlighted the importance of the convergence of industry leaders to discuss key technology areas.
Bocar A. Ba, President of SAMENA Telecommunications Council said, “Etisalat has always been an active participant and keen supporter of various efforts in promoting collaborative solutions and knowledge-sharing within the telecommunications industry. As a leading operator, Etisalat has been at the forefront of a number of innovative solutions and services, and has contributed enormously to the growth and advancement of the sector locally and regionally. It is indeed great to see the organization winning four SAMENA awards in recognition of their constant efforts to further develop and promote the regional telecommunications industry and provide seamless services to their customers. I would also like to extend my warm congratulations to the Chairman on his selection as the ’Best Outstanding Telecom Operator Leader’ of the year.”
SAMENA Telecommunications Council is a multi-continent telecom consortium that aims to be the leading provider of telecom innovations in its member regions as well as a facilitator for collaboration and knowledge-sharing between regional telecom entities.
The SAMENA Awards demonstrate Etisalat’s ongoing efforts in the development of the telecommunications sector in the UAE and beyond, in terms of infrastructure and advanced telecommunications, which are critical foundations for economic success. The awards recognize Etisalat’s innovations and strategies in customer service which focus on applying the latest systems and emphasis on achieving the highest standards in customer satisfaction.
As a leader in offering the latest services to all residents of the UAE, Etisalat covers 100% of GSM network coverage across UAE and 99% 3G coverage of UAE's populated areas.
Etisalat operates in 18 countries across Asia, the Middle East and Africa, servicing over 107 million customers out of a total population of approximately 2 billion people.
Etisalat is a major investor in Thuraya, one of the world’s leading satellite geo-mobile communication systems covering approximately two thirds of the planet’s surface. The company is also the largest carrier for voice data in the Middle East, and has the largest roaming network in the region with 600 agreements that cover more than 190 countries worldwide.
For media enquiries, please contact:
Iyad AlZoubi,
Senior Manager International Media Relations, Etisalat
Tel: 02 6182173
Fax: 02 6334448
ialzoubi@etisalat.ae
The Nielsen Company Reports Third Quarter 2010 Results
NEW YORK, Sunday, October 31st 2010 [ME NewsWire]:
(BUSINESS WIRE)-- The Nielsen Company B.V., a leading global information and measurement company, today announced its financial results for the quarter and nine months ended September 30, 2010.
Reported revenues for the three months ended September 30, 2010 were $1,289 million, an increase of 5% over reported revenues for the three months ended September 30, 2009 of $1,227 million. Excluding the impact of currency fluctuations*, revenues for the three months increased 7%.
Reported operating income for the three months ended September 30, 2010 was $201 million compared to an operating loss of $326 million for the three months ended September 30, 2009. The 2010 results included $11 million of charges relating to restructuring costs. The 2009 results included $524 million of charges relating to the September 2009 impairment of goodwill and other intangible assets as well as restructuring. Adjusting for these items and excluding the impact of currency fluctuations*, operating income increased 10%.
Reported revenues for the nine months ended September 30, 2010 were $3,755 million, an increase of 7% over reported revenues for the nine months ended September 30, 2009 of $3,511 million. Excluding the impact of currency fluctuations*, revenues for the nine months increased 6%.
Reported operating income for the nine months ended September 30, 2010 was $515 million compared to an operating loss of $42 million for the nine months ended September 30, 2009. The 2010 results included $33 million of charges relating to restructuring costs. The 2009 results included $533 million of charges relating to the September 2009 impairment of goodwill and other intangible assets as well as restructuring. Adjusting for these items, operating income, on a constant currency basis*, increased 10%.
Covenant earnings before interest, taxes, depreciation and amortization and other adjustments permitted under our senior secured credit facilities (“Covenant EBITDA”) was $1,415 million for the twelve months ended September 30, 2010. Covenant EBITDA is a non – GAAP measure. See “Covenant EBITDA” below for a reconciliation of Income from continuing operations of $191 million for the twelve months ended September 30, 2010 to Covenant EBITDA.
As of September 30, 2010, total debt was $8,571 million, and cash balances were $420 million. Capital expenditures were $226 million for the nine months ended September 30, 2010, compared with $204 million for the nine months ended September 30, 2009.
Conference Call and Webcast
The Nielsen Company will hold an earnings conference call, hosted by The Nielsen Company’s Chief Financial Officer Brian J. West, at 9:00 a.m. U.S. Eastern Time (ET) on October 28, 2010. The call will be audio-webcast live at http://en-us.nielsen.com/main/about/investor_relations and an archive will be available on the website after the call. In addition, a link to the company’s quarterly financial report on Form 10-Q has been posted at http://en-us.nielsen.com/main/about/investor_relations.
Forward-looking Statements
This news release includes information that could constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as ‘expect’, ‘should’, ‘could’, ‘shall’ and similar expressions. These statements are subject to risks and uncertainties, and actual results and events could differ materially from what presently is expected. Factors leading thereto may include without limitations general economic conditions, conditions in the markets Nielsen is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting Nielsen’s business. This list of factors is not intended to be exhaustive. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events, or other factors.
About The Nielsen Company
The Nielsen Company is a global information and measurement company with leading market positions in marketing and consumer information, television and other media measurement, online intelligence, mobile measurement, trade shows and related properties. The privately held company has a presence in approximately 100 countries, with headquarters in Diemen, the Netherlands and New York, USA. For more information, please visit www.nielsen.com.
* We evaluate our results of operations on both an as reported and a constant currency basis. The constant currency presentation, which is a non-GAAP measure, excludes the impact of fluctuations in foreign currency exchange rates. We believe providing constant currency information provides valuable supplemental information regarding our results of operations, consistent with how we evaluate our performance. We calculate constant currency percentages by converting our prior-period local currency financial results using the current period exchange rates and comparing these adjusted amounts to our current period reported results.
Results of Operations – Three Months Ended September 30, 2010 and 2009
The following table sets forth, the amounts included in our Condensed Statements of Operations for the three months ended September 30, 2010 and 2009:
Three Months Ended
September 30,
(unaudited)
(IN MILLIONS)
2010
2009
Revenues
$
1,289
$
1,227
Cost of revenues, exclusive of depreciation and amortization shown separately below
521
521
Selling, general and administrative expenses exclusive of depreciation and amortization shown separately below
414
365
Depreciation and amortization
142
143
Impairment of goodwill and other intangibles
-
527
Restructuring costs/(credits)
11
(3)
Operating income/(loss)
201
(326)
Interest income
1
2
Interest expense
(169)
(168)
Loss on derivative instruments
(5)
(21)
Foreign currency exchange transaction losses, net
(5)
(21)
Income /(loss) from continuing operations before income taxes, and equity in net income/(loss) of affiliates
23
(534)
(Provision)/benefit for income taxes
(2)
99
Equity in net income/(loss) of affiliates
1
(33)
Income/(loss) from continuing operations
22
(468)
Discontinued operations, net of tax
(11)
(58)
Net income/(loss)
11
(526)
Less: net income attributable to noncontrolling interests
-
1
Net income/(loss) attributable to The Nielsen Company B.V.
$
11
$
(527)
Results of Operations – Nine Months Ended September 30, 2010 and 2009
The following table sets forth, the amounts included in our Condensed Statements of Operations for the nine months ended September 30, 2010 and 2009:
Nine Months Ended
September 30,
(unaudited)
(IN MILLIONS)
2010
2009
Revenues
$
3,755
$
3,511
Cost of revenues, exclusive of depreciation and amortization shown separately below
1,569
1,484
Selling, general and administrative expenses exclusive of depreciation and amortization shown separately below
1,219
1,127
Depreciation and amortization
419
409
Impairment of goodwill and other intangibles
-
527
Restructuring costs
33
6
Operating income/(loss)
515
(42)
Interest income
3
6
Interest expense
(491)
(480)
Loss on derivative instruments
(17)
(54)
Foreign currency exchange transaction gains, net
140
10
Other Income/(expense), net
9
(11)
Income/(loss) from continuing operations before income taxes, and equity in net income/(loss) of affiliates
159
(571)
(Provision)/benefit for income taxes
(14)
124
Equity in net income/(loss) of affiliates
1
(25)
Income/(loss) from continuing operations
146
(472)
Discontinued operations, net of tax
(19)
(58)
Net income/(loss)
127
(530)
Less: net income attributable to noncontrolling interests
1
2
Net income/(loss) attributable to The Nielsen Company B.V.
$
126
$
(532)
Covenant EBITDA
The following is a reconciliation of our loss from continuing operations, for the twelve months ended September 30, 2010, to Covenant EBITDA as defined below per our senior secured credit facilities:
(IN MILLIONS)
Covenant EBITDA
Twelve Months
ended
September 30, 2010
(unaudited)
Income from continuing operations
$
191
Interest expense, net
651
Benefit for income taxes
(57)
Depreciation and amortization
567
EBITDA
1,352
Non-cash charges
18
Unusual or non-recurring items
(80)
Restructuring charges and business optimization costs
102
Sponsor monitoring fees
12
Other
11
Covenant EBITDA
$
1,415
Note: Covenant EBITDA is a non-generally accepted accounting principle (“GAAP”) measure used to determine our compliance with certain covenants contained in our senior secured credit facilities. Covenant EBITDA is defined in our senior secured credit facility as net income (loss) from continuing operations, as adjusted for the items summarized in the table above. Covenant EBITDA is not a presentation made in accordance with GAAP, and our use of the term Covenant EBITDA varies from others in our industry due to the potential inconsistencies in the method of calculation and differences due to items subject to interpretation. Covenant EBITDA should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP as measures of operating performance or cash flows as measures of liquidity. Covenant EBITDA has important limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. For example, Covenant EBITDA:
* excludes income tax payments;
* does not reflect any cash capital expenditure requirements;
* does not reflect changes in, or cash requirements for, our working capital needs;
* does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
* does not reflect management fees that are payable to the Sponsors;
* does not reflect the impact of earnings or charges resulting from matters that we and the lenders under our new senior secured credit facility may consider not to be indicative of our ongoing operations.
In particular, the definition of Covenant EBITDA allows us to add back certain non-cash and non-recurring charges that are deducted in determining net income. However, these are expenses that may recur, vary greatly and are difficult to predict. They can represent the effect of long-term strategies as opposed to short-term results. In addition, certain of these expenses can represent a reduction of cash that could be used for other corporate purposes.
Because of these limitations we rely primarily on our GAAP results. However, we believe that the inclusion of supplementary adjustments to EBITDA applied in presenting Covenant EBITDA is appropriate to provide additional information to investors to demonstrate compliance with our financing covenants.
For media enquiries, please contact:
The Nielsen Company B.V.
Investor Relations:
Rich Nelson,
+1-646-654-7761
Media Relations:
Ed Dandridge,
+1-646-654-8656
(BUSINESS WIRE)-- The Nielsen Company B.V., a leading global information and measurement company, today announced its financial results for the quarter and nine months ended September 30, 2010.
Reported revenues for the three months ended September 30, 2010 were $1,289 million, an increase of 5% over reported revenues for the three months ended September 30, 2009 of $1,227 million. Excluding the impact of currency fluctuations*, revenues for the three months increased 7%.
Reported operating income for the three months ended September 30, 2010 was $201 million compared to an operating loss of $326 million for the three months ended September 30, 2009. The 2010 results included $11 million of charges relating to restructuring costs. The 2009 results included $524 million of charges relating to the September 2009 impairment of goodwill and other intangible assets as well as restructuring. Adjusting for these items and excluding the impact of currency fluctuations*, operating income increased 10%.
Reported revenues for the nine months ended September 30, 2010 were $3,755 million, an increase of 7% over reported revenues for the nine months ended September 30, 2009 of $3,511 million. Excluding the impact of currency fluctuations*, revenues for the nine months increased 6%.
Reported operating income for the nine months ended September 30, 2010 was $515 million compared to an operating loss of $42 million for the nine months ended September 30, 2009. The 2010 results included $33 million of charges relating to restructuring costs. The 2009 results included $533 million of charges relating to the September 2009 impairment of goodwill and other intangible assets as well as restructuring. Adjusting for these items, operating income, on a constant currency basis*, increased 10%.
Covenant earnings before interest, taxes, depreciation and amortization and other adjustments permitted under our senior secured credit facilities (“Covenant EBITDA”) was $1,415 million for the twelve months ended September 30, 2010. Covenant EBITDA is a non – GAAP measure. See “Covenant EBITDA” below for a reconciliation of Income from continuing operations of $191 million for the twelve months ended September 30, 2010 to Covenant EBITDA.
As of September 30, 2010, total debt was $8,571 million, and cash balances were $420 million. Capital expenditures were $226 million for the nine months ended September 30, 2010, compared with $204 million for the nine months ended September 30, 2009.
Conference Call and Webcast
The Nielsen Company will hold an earnings conference call, hosted by The Nielsen Company’s Chief Financial Officer Brian J. West, at 9:00 a.m. U.S. Eastern Time (ET) on October 28, 2010. The call will be audio-webcast live at http://en-us.nielsen.com/main/about/investor_relations and an archive will be available on the website after the call. In addition, a link to the company’s quarterly financial report on Form 10-Q has been posted at http://en-us.nielsen.com/main/about/investor_relations.
Forward-looking Statements
This news release includes information that could constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as ‘expect’, ‘should’, ‘could’, ‘shall’ and similar expressions. These statements are subject to risks and uncertainties, and actual results and events could differ materially from what presently is expected. Factors leading thereto may include without limitations general economic conditions, conditions in the markets Nielsen is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting Nielsen’s business. This list of factors is not intended to be exhaustive. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events, or other factors.
About The Nielsen Company
The Nielsen Company is a global information and measurement company with leading market positions in marketing and consumer information, television and other media measurement, online intelligence, mobile measurement, trade shows and related properties. The privately held company has a presence in approximately 100 countries, with headquarters in Diemen, the Netherlands and New York, USA. For more information, please visit www.nielsen.com.
* We evaluate our results of operations on both an as reported and a constant currency basis. The constant currency presentation, which is a non-GAAP measure, excludes the impact of fluctuations in foreign currency exchange rates. We believe providing constant currency information provides valuable supplemental information regarding our results of operations, consistent with how we evaluate our performance. We calculate constant currency percentages by converting our prior-period local currency financial results using the current period exchange rates and comparing these adjusted amounts to our current period reported results.
Results of Operations – Three Months Ended September 30, 2010 and 2009
The following table sets forth, the amounts included in our Condensed Statements of Operations for the three months ended September 30, 2010 and 2009:
Three Months Ended
September 30,
(unaudited)
(IN MILLIONS)
2010
2009
Revenues
$
1,289
$
1,227
Cost of revenues, exclusive of depreciation and amortization shown separately below
521
521
Selling, general and administrative expenses exclusive of depreciation and amortization shown separately below
414
365
Depreciation and amortization
142
143
Impairment of goodwill and other intangibles
-
527
Restructuring costs/(credits)
11
(3)
Operating income/(loss)
201
(326)
Interest income
1
2
Interest expense
(169)
(168)
Loss on derivative instruments
(5)
(21)
Foreign currency exchange transaction losses, net
(5)
(21)
Income /(loss) from continuing operations before income taxes, and equity in net income/(loss) of affiliates
23
(534)
(Provision)/benefit for income taxes
(2)
99
Equity in net income/(loss) of affiliates
1
(33)
Income/(loss) from continuing operations
22
(468)
Discontinued operations, net of tax
(11)
(58)
Net income/(loss)
11
(526)
Less: net income attributable to noncontrolling interests
-
1
Net income/(loss) attributable to The Nielsen Company B.V.
$
11
$
(527)
Results of Operations – Nine Months Ended September 30, 2010 and 2009
The following table sets forth, the amounts included in our Condensed Statements of Operations for the nine months ended September 30, 2010 and 2009:
Nine Months Ended
September 30,
(unaudited)
(IN MILLIONS)
2010
2009
Revenues
$
3,755
$
3,511
Cost of revenues, exclusive of depreciation and amortization shown separately below
1,569
1,484
Selling, general and administrative expenses exclusive of depreciation and amortization shown separately below
1,219
1,127
Depreciation and amortization
419
409
Impairment of goodwill and other intangibles
-
527
Restructuring costs
33
6
Operating income/(loss)
515
(42)
Interest income
3
6
Interest expense
(491)
(480)
Loss on derivative instruments
(17)
(54)
Foreign currency exchange transaction gains, net
140
10
Other Income/(expense), net
9
(11)
Income/(loss) from continuing operations before income taxes, and equity in net income/(loss) of affiliates
159
(571)
(Provision)/benefit for income taxes
(14)
124
Equity in net income/(loss) of affiliates
1
(25)
Income/(loss) from continuing operations
146
(472)
Discontinued operations, net of tax
(19)
(58)
Net income/(loss)
127
(530)
Less: net income attributable to noncontrolling interests
1
2
Net income/(loss) attributable to The Nielsen Company B.V.
$
126
$
(532)
Covenant EBITDA
The following is a reconciliation of our loss from continuing operations, for the twelve months ended September 30, 2010, to Covenant EBITDA as defined below per our senior secured credit facilities:
(IN MILLIONS)
Covenant EBITDA
Twelve Months
ended
September 30, 2010
(unaudited)
Income from continuing operations
$
191
Interest expense, net
651
Benefit for income taxes
(57)
Depreciation and amortization
567
EBITDA
1,352
Non-cash charges
18
Unusual or non-recurring items
(80)
Restructuring charges and business optimization costs
102
Sponsor monitoring fees
12
Other
11
Covenant EBITDA
$
1,415
Note: Covenant EBITDA is a non-generally accepted accounting principle (“GAAP”) measure used to determine our compliance with certain covenants contained in our senior secured credit facilities. Covenant EBITDA is defined in our senior secured credit facility as net income (loss) from continuing operations, as adjusted for the items summarized in the table above. Covenant EBITDA is not a presentation made in accordance with GAAP, and our use of the term Covenant EBITDA varies from others in our industry due to the potential inconsistencies in the method of calculation and differences due to items subject to interpretation. Covenant EBITDA should not be considered as an alternative to net income/(loss), operating income or any other performance measures derived in accordance with GAAP as measures of operating performance or cash flows as measures of liquidity. Covenant EBITDA has important limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. For example, Covenant EBITDA:
* excludes income tax payments;
* does not reflect any cash capital expenditure requirements;
* does not reflect changes in, or cash requirements for, our working capital needs;
* does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
* does not reflect management fees that are payable to the Sponsors;
* does not reflect the impact of earnings or charges resulting from matters that we and the lenders under our new senior secured credit facility may consider not to be indicative of our ongoing operations.
In particular, the definition of Covenant EBITDA allows us to add back certain non-cash and non-recurring charges that are deducted in determining net income. However, these are expenses that may recur, vary greatly and are difficult to predict. They can represent the effect of long-term strategies as opposed to short-term results. In addition, certain of these expenses can represent a reduction of cash that could be used for other corporate purposes.
Because of these limitations we rely primarily on our GAAP results. However, we believe that the inclusion of supplementary adjustments to EBITDA applied in presenting Covenant EBITDA is appropriate to provide additional information to investors to demonstrate compliance with our financing covenants.
For media enquiries, please contact:
The Nielsen Company B.V.
Investor Relations:
Rich Nelson,
+1-646-654-7761
Media Relations:
Ed Dandridge,
+1-646-654-8656
Celgene Reports Record Third Quarter 2010 Operating and Financial Results
SUMMIT, N.J., Sunday, October 31st 2010 [ME NewsWire]:
Record Third Quarter Results Driven By Share Gains Across Major Markets
REVLIMID® Third Quarter Global Net Product Sales Increased 43% Y/Y
VIDAZA® Third Quarter Global Net Product Sales Increased 37% Y/Y
Non-GAAP Third Quarter Diluted Earnings Per Share Increased 34% Y/Y
(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG):
2010 Third Quarter Financial Results Year-Over-Year
* Non-GAAP Total Revenue Increased 31 Percent to $908 Million; GAAP Total Revenue $910 Million
* Global REVLIMID Net Product Sales Increased 43 Percent to $641 Million
* Global VIDAZA Net Product Sales Increased 37 Percent to $141 Million
* Global THALOMID® Net Product Sales of $94 Million
* Non-GAAP Operating Income Increased 40 Percent to $409 Million; GAAP Operating Income $311 Million
* Non-GAAP Net Income Increased 35 Percent to $350 Million; GAAP Net Income $281 Million
* Non-GAAP Diluted Earnings Per Share Increased 34 Percent to $0.75; GAAP Diluted Earnings Per Share $0.60
2010 Financial Outlook Update (Includes Impact of Acquisition of Abraxis BioScience)
* Total Revenue Expected to Increase Approximately 34 Percent Year-Over-Year to Approximately $3.60 Billion, Up From a Previous Range of $3.40 to $3.45 Billion
* REVLIMID Net Product Sales Anticipated to Increase Approximately 44 Percent Year-Over-Year to Approximately $2.45 Billion, Up From a Previous Range of $2.30 to $2.35 Billion
* Non-GAAP Diluted Earnings Per Share Expected to Increase Approximately 34 Percent Year-Over-Year to a Range of $2.78 to $2.80, Up From a Previous Range of $2.65 to $2.70
Recent Developments and Highlights
* Completed Acquisition of Abraxis BioScience
* Completed $1.25 Billion Debut Debt Offering
* Announced Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer
* Initiated Launch of REVLIMID® in Japan for Treatment of Relapsed/Refractory Multiple Myeloma
* Initiated PALACE 1, PALACE 2, and PALACE 3, Phase III Trials Evaluating Apremilast in Psoriatic Arthritis, and ESTEEM 1, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis
* Brought Infringement Action to Enforce our REVLIMID Patents Against Natco Pharma Ltd. for Filing an Abbreviated New Drug Application With a Paragraph IV Certification for Lenalidomide
* ABRAXANE® Pharmaceutical Composition and Method Claims Patent Issued on October 26, 2010, expiring in 2024
* Initiated MF-002, a Phase III Trial Evaluating Pomalidomide in Myelofibrosis
* Initiated AZA-AML-001, a Phase III Trial Evaluating VIDAZA® in Newly Diagnosed Acute Myeloid Leukemia
* Initiated Phase II Trial for PDA-001 Cellular Therapy in Crohn’s Disease
2010 Selected Corporate Objectives
* Expand Celgene Product Approvals, Reimbursements, and Global Market Share
* Submit REVLIMID Newly Diagnosed Multiple Myeloma (NDMM) Regulatory Filing with European Medicines Agency
* Complete Enrollment of MM-020, a Phase III Trial Evaluating REVLIMID and Low-Dose Dexamethasone Versus Melphalan, Prednisone, and Thalidomide in NDMM
* Submit ISTODAX® Peripheral T-cell Lymphoma Regulatory Filing with Food and Drug Administration
* Advance More Than 25 Phase III and Pivotal Clinical Trials and 17 Preclinical Programs Addressing More Than 30 Serious and Debilitating Diseases
* Initiate ESTEEM 2, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis, and PALACE 4, a Phase III Trial Evaluating Apremilast in Psoriatic Arthritis
* Initiate Phase II Trial for Apremilast in Rheumatoid Arthritis
* Initiate Phase II Trial for PDA-001 Cellular Therapy in Ischemic Stroke; Initiate Phase I Trial in Multiple Sclerosis
* Initiate Phase II Trial for JNK CC-930 in Idiopathic Pulmonary Fibrosis and Discoid Lupus Erythematosus
Celgene Corporation (NASDAQ: CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010. Non-GAAP net income for the third quarter of 2009 was $259.8 million or non-GAAP diluted earnings per share of $0.56. Based on U.S. GAAP, Celgene reported net income of $281.2 million, or diluted earnings per share of $0.60 for the quarter ended September 30, 2010. GAAP net income for the third quarter of 2009 was $216.8 million, or diluted earnings per share of $0.46.
Celgene posted non-GAAP net income of $967.7 million or non-GAAP diluted earnings per share of $2.07 during the first nine months of 2010 as compared to non-GAAP net income of $681.0 million and non-GAAP diluted earnings per share of $1.46 in 2009. On a GAAP basis, Celgene reported net income of $670.9 million, or diluted earnings per share of $1.44 for the first nine months of 2010, compared to GAAP net income of $522.5 million, or diluted earnings per share of $1.12 in 2009.
“Our third quarter results reflect outstanding operational execution by our global team,” said Bob Hugin, Celgene’s Chief Executive Officer. “Our expanding portfolio of innovative therapies in oncology and immune-inflammatory diseases further positions us for sustained growth and value creation in the near and long term.”
Product Sales Performance
Non-GAAP total revenue was a record $908.1 million for the quarter ended September 30, 2010, an increase of 31 percent from 2009. GAAP total revenue was $910.1 million for the quarter ended September 30, 2010. The increase in total revenue was driven by global market share gains and increased duration of therapy of REVLIMID® and VIDAZA®. Net sales of REVLIMID were $641.3 million, an increase of 43 percent over the same period in 2009. VIDAZA® net sales were $141.4 million, an increase of 37 percent from 2009. Global THALOMID® (inclusive of Thalidomide Celgene® and Thalidomide Pharmion®) sales were $94.2 million, a 14 percent decrease from 2009. Revenue from Focalin® and the Ritalin® family of drugs totaled $22.6 million for the third quarter of 2010 compared to $25.8 million over the same period in 2009.
For the first nine months of 2010, non-GAAP total revenue was a record $2.547 billion, an increase of 33 percent year-over-year. GAAP total revenue was $2.554 billion for the nine months ended September 30, 2010. REVLIMID net sales for the first nine months of 2010 were $1.759 billion, an increase of 45 percent over $1.209 billion for the same period in 2009. VIDAZA net sales for the first nine months of 2010 were $393.6 million, an increase of 46 percent over the same period in 2009. THALOMID net sales for the first nine months of 2010 were $296.0 million, a decrease of 10 percent from the same period in 2009. Revenue from Focalin and the Ritalin family of drugs totaled $79.3 million for the first nine months of 2010, an increase of 3 percent over the same period in 2009.
Research and Development
For the third quarter of 2010, non-GAAP R&D expenses, which exclude upfront collaboration payments and share-based employee compensation expense, were $232.3 million compared to $178.2 million for the third quarter of 2009. These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID, pomalidomide, and other compounds; VIDAZA; ISTODAX®; amrubicin; apremilast and our oral anti-inflammatory compounds; our kinase inhibitor programs; our activin inhibitor program with ACE-011; and cellular therapy programs. On a GAAP basis, R&D expenses were $253.5 million for the third quarter of 2010 and $193.4 million in the same period in 2009.
Click here for full press release including tables.
For media enquiries, please contact:
Celgene Corporation
Jacqualyn A. Fouse, 908-673-9956
Sr. Vice President and Chief Financial Officer
Tim Smith, 908-673-9951
Director, Investor Relations
Record Third Quarter Results Driven By Share Gains Across Major Markets
REVLIMID® Third Quarter Global Net Product Sales Increased 43% Y/Y
VIDAZA® Third Quarter Global Net Product Sales Increased 37% Y/Y
Non-GAAP Third Quarter Diluted Earnings Per Share Increased 34% Y/Y
(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG):
2010 Third Quarter Financial Results Year-Over-Year
* Non-GAAP Total Revenue Increased 31 Percent to $908 Million; GAAP Total Revenue $910 Million
* Global REVLIMID Net Product Sales Increased 43 Percent to $641 Million
* Global VIDAZA Net Product Sales Increased 37 Percent to $141 Million
* Global THALOMID® Net Product Sales of $94 Million
* Non-GAAP Operating Income Increased 40 Percent to $409 Million; GAAP Operating Income $311 Million
* Non-GAAP Net Income Increased 35 Percent to $350 Million; GAAP Net Income $281 Million
* Non-GAAP Diluted Earnings Per Share Increased 34 Percent to $0.75; GAAP Diluted Earnings Per Share $0.60
2010 Financial Outlook Update (Includes Impact of Acquisition of Abraxis BioScience)
* Total Revenue Expected to Increase Approximately 34 Percent Year-Over-Year to Approximately $3.60 Billion, Up From a Previous Range of $3.40 to $3.45 Billion
* REVLIMID Net Product Sales Anticipated to Increase Approximately 44 Percent Year-Over-Year to Approximately $2.45 Billion, Up From a Previous Range of $2.30 to $2.35 Billion
* Non-GAAP Diluted Earnings Per Share Expected to Increase Approximately 34 Percent Year-Over-Year to a Range of $2.78 to $2.80, Up From a Previous Range of $2.65 to $2.70
Recent Developments and Highlights
* Completed Acquisition of Abraxis BioScience
* Completed $1.25 Billion Debut Debt Offering
* Announced Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer
* Initiated Launch of REVLIMID® in Japan for Treatment of Relapsed/Refractory Multiple Myeloma
* Initiated PALACE 1, PALACE 2, and PALACE 3, Phase III Trials Evaluating Apremilast in Psoriatic Arthritis, and ESTEEM 1, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis
* Brought Infringement Action to Enforce our REVLIMID Patents Against Natco Pharma Ltd. for Filing an Abbreviated New Drug Application With a Paragraph IV Certification for Lenalidomide
* ABRAXANE® Pharmaceutical Composition and Method Claims Patent Issued on October 26, 2010, expiring in 2024
* Initiated MF-002, a Phase III Trial Evaluating Pomalidomide in Myelofibrosis
* Initiated AZA-AML-001, a Phase III Trial Evaluating VIDAZA® in Newly Diagnosed Acute Myeloid Leukemia
* Initiated Phase II Trial for PDA-001 Cellular Therapy in Crohn’s Disease
2010 Selected Corporate Objectives
* Expand Celgene Product Approvals, Reimbursements, and Global Market Share
* Submit REVLIMID Newly Diagnosed Multiple Myeloma (NDMM) Regulatory Filing with European Medicines Agency
* Complete Enrollment of MM-020, a Phase III Trial Evaluating REVLIMID and Low-Dose Dexamethasone Versus Melphalan, Prednisone, and Thalidomide in NDMM
* Submit ISTODAX® Peripheral T-cell Lymphoma Regulatory Filing with Food and Drug Administration
* Advance More Than 25 Phase III and Pivotal Clinical Trials and 17 Preclinical Programs Addressing More Than 30 Serious and Debilitating Diseases
* Initiate ESTEEM 2, a Phase III Trial Evaluating Apremilast in Moderate-to-Severe Psoriasis, and PALACE 4, a Phase III Trial Evaluating Apremilast in Psoriatic Arthritis
* Initiate Phase II Trial for Apremilast in Rheumatoid Arthritis
* Initiate Phase II Trial for PDA-001 Cellular Therapy in Ischemic Stroke; Initiate Phase I Trial in Multiple Sclerosis
* Initiate Phase II Trial for JNK CC-930 in Idiopathic Pulmonary Fibrosis and Discoid Lupus Erythematosus
Celgene Corporation (NASDAQ: CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010. Non-GAAP net income for the third quarter of 2009 was $259.8 million or non-GAAP diluted earnings per share of $0.56. Based on U.S. GAAP, Celgene reported net income of $281.2 million, or diluted earnings per share of $0.60 for the quarter ended September 30, 2010. GAAP net income for the third quarter of 2009 was $216.8 million, or diluted earnings per share of $0.46.
Celgene posted non-GAAP net income of $967.7 million or non-GAAP diluted earnings per share of $2.07 during the first nine months of 2010 as compared to non-GAAP net income of $681.0 million and non-GAAP diluted earnings per share of $1.46 in 2009. On a GAAP basis, Celgene reported net income of $670.9 million, or diluted earnings per share of $1.44 for the first nine months of 2010, compared to GAAP net income of $522.5 million, or diluted earnings per share of $1.12 in 2009.
“Our third quarter results reflect outstanding operational execution by our global team,” said Bob Hugin, Celgene’s Chief Executive Officer. “Our expanding portfolio of innovative therapies in oncology and immune-inflammatory diseases further positions us for sustained growth and value creation in the near and long term.”
Product Sales Performance
Non-GAAP total revenue was a record $908.1 million for the quarter ended September 30, 2010, an increase of 31 percent from 2009. GAAP total revenue was $910.1 million for the quarter ended September 30, 2010. The increase in total revenue was driven by global market share gains and increased duration of therapy of REVLIMID® and VIDAZA®. Net sales of REVLIMID were $641.3 million, an increase of 43 percent over the same period in 2009. VIDAZA® net sales were $141.4 million, an increase of 37 percent from 2009. Global THALOMID® (inclusive of Thalidomide Celgene® and Thalidomide Pharmion®) sales were $94.2 million, a 14 percent decrease from 2009. Revenue from Focalin® and the Ritalin® family of drugs totaled $22.6 million for the third quarter of 2010 compared to $25.8 million over the same period in 2009.
For the first nine months of 2010, non-GAAP total revenue was a record $2.547 billion, an increase of 33 percent year-over-year. GAAP total revenue was $2.554 billion for the nine months ended September 30, 2010. REVLIMID net sales for the first nine months of 2010 were $1.759 billion, an increase of 45 percent over $1.209 billion for the same period in 2009. VIDAZA net sales for the first nine months of 2010 were $393.6 million, an increase of 46 percent over the same period in 2009. THALOMID net sales for the first nine months of 2010 were $296.0 million, a decrease of 10 percent from the same period in 2009. Revenue from Focalin and the Ritalin family of drugs totaled $79.3 million for the first nine months of 2010, an increase of 3 percent over the same period in 2009.
Research and Development
For the third quarter of 2010, non-GAAP R&D expenses, which exclude upfront collaboration payments and share-based employee compensation expense, were $232.3 million compared to $178.2 million for the third quarter of 2009. These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID, pomalidomide, and other compounds; VIDAZA; ISTODAX®; amrubicin; apremilast and our oral anti-inflammatory compounds; our kinase inhibitor programs; our activin inhibitor program with ACE-011; and cellular therapy programs. On a GAAP basis, R&D expenses were $253.5 million for the third quarter of 2010 and $193.4 million in the same period in 2009.
Click here for full press release including tables.
For media enquiries, please contact:
Celgene Corporation
Jacqualyn A. Fouse, 908-673-9956
Sr. Vice President and Chief Financial Officer
Tim Smith, 908-673-9951
Director, Investor Relations
Subscribe to:
Posts (Atom)